NCT05279131Phase 3Completed
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm2 on the Face or Balding Scalp in Adult Patients With Actinic Keratosis
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- Almirall, S.A.
- Participants (registry)
- 105
- Start
- June 2022
- Primary completion
- December 2022
- Study completion
- December 2022
- Last registry update
- January 2024
- Countries
- United States
Conditions studied: Keratosis, Actinic
Interventions: Tirbanibulin ointment 1%
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.